LENVIMA is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).
LENVIMA treatment should be initiated and supervised by a health care professional experienced in the use of anticancer therapies